<p>在过去的 7 天里，美国市场保持平稳，但在过去一年中却显著上涨了 28%，预计未来几年收益将以每年 16% 的速度增长。在这样的环境下，识别那些交易价格低于其内在价值的股票，可以为寻求利用低估机会的投资者提供潜在的机会。</p>
<h3>基于现金流的美国十大低估股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>当前价格</strong></td>
<td><strong>公允价值（估计）</strong></td>
<td><strong>折扣（估计）</strong></td>
</tr>
<tr>
<td>Unity Software (U)</td>
<td>$27.72</td>
<td>$55.28</td>
<td>49.9%</td>
</tr>
<tr>
<td>Travere Therapeutics (TVTX)</td>
<td>$44.91</td>
<td>$88.58</td>
<td>49.3%</td>
</tr>
<tr>
<td>Sea (SE)</td>
<td>$85.41</td>
<td>$169.85</td>
<td>49.7%</td>
</tr>
<tr>
<td>Genuine Parts (GPC)</td>
<td>$103.52</td>
<td>$199.62</td>
<td>48.1%</td>
</tr>
<tr>
<td>First Merchants (FRME)</td>
<td>$40.02</td>
<td>$77.51</td>
<td>48.4%</td>
</tr>
<tr>
<td>Fifth Third Bancorp (FITB)</td>
<td>$49.40</td>
<td>$94.92</td>
<td>48%</td>
</tr>
<tr>
<td>FB Financial (FBK)</td>
<td>$53.53</td>
<td>$103.19</td>
<td>48.1%</td>
</tr>
<tr>
<td>Chemung Financial (CHMG)</td>
<td>$65.75</td>
<td>$127.22</td>
<td>48.3%</td>
</tr>
<tr>
<td>AST SpaceMobile (ASTS)</td>
<td>$68.43</td>
<td>$132.99</td>
<td>48.5%</td>
</tr>
<tr>
<td>AbbVie (ABBV)</td>
<td>$208.16</td>
<td>$400.51</td>
<td>48%</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们基于现金流的 151 只低估美国股票的完整列表。</p>
<p>让我们从我们的专业筛选器中发现一些宝藏。</p>
<h2>Travere Therapeutics (TVTX)</h2>
<p><strong>概述：</strong> Travere Therapeutics, Inc.是一家生物制药公司，专注于识别、开发和提供针对美国罕见肾脏和代谢疾病的治疗，市值为 40.8 亿美元。</p>
<p><strong>运营：</strong> 该公司通过开发和商业化针对美国罕见肾脏和代谢疾病的创新疗法，产生了 4.9073 亿美元的收入。</p>
<p><strong>公允价值折扣估计：</strong> 49.3%</p>
<p>Travere Therapeutics 的交易价格为 44.91 美元，显著低于其估计的未来现金流价值 88.58 美元，表明其可能在现金流基础上被低估。该公司报告 2026 年第一季度收入为 1.272 亿美元，较去年同期的 8173 万美元有所增长，净亏损减少至 3710 万美元，去年为 4123 万美元。随着 FDA 批准 FILSPARI 扩大其市场潜力，Travere 的收入预计将以每年 20.3% 的速度增长，超过美国市场的整体增长预期。</p>
<ul>
<li>根据我们最近的增长报告，Travere Therapeutics 的财务表现似乎有可能超过当前水平。</li>
<li>通过阅读我们的健康报告，深入了解 Travere Therapeutics 的资产负债表。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8a367f73-a6f2-4b6f-b781-0538bd368fa3/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8a367f73-a6f2-4b6f-b781-0538bd368fa3/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>截至 2026 年 5 月的 TVTX 折现现金流</p>
<h2>CVR Energy (CVI)</h2>
<p><strong>概述：</strong> CVR Energy, Inc.在美国运营，专注于可再生燃料和石油精炼及营销，以及氮肥制造，市值为 33.5 亿美元。</p>
<p><strong>运营：</strong> 该公司通过在可再生燃料、石油精炼和营销以及氮肥制造方面的业务产生收入。</p>
<p><strong>公允价值折扣估计：</strong> 28.3%</p>
<p>CVR Energy 的交易价格为 34.2 美元，低于其估计的未来现金流价值 47.72 美元，突显出基于现金流的潜在低估。尽管最近 2026 年第一季度净亏损为 1.92 亿美元，且面临盈利挑战，但该公司预计将在三年内实现盈利，并且预计股本回报率将很高。然而，收入增长仍然缓慢，年增长率为 0.6%，落后于美国市场 11.2% 的预期。</p>
<ul>
<li>根据我们的收益增长报告，CVR Energy 可能准备扩张的迹象。</li>
<li>通过我们的全面财务健康报告，深入了解 CVR Energy 的复杂情况。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/85096f12-bc2f-4422-bac7-9d19553b4370/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/85096f12-bc2f-4422-bac7-9d19553b4370/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>截至 2026 年 5 月的 CVI 折现现金流</p>
<h2>Unity Software (U)</h2>
<p><strong>概述：</strong> Unity Software Inc.提供一个平台，用于在全球各种设备上开发、部署和增强游戏及互动体验，市值约为 118.4 亿美元。</p>
<p><strong>运营：</strong> 该公司的软件解决方案收入为 18.5 亿美元。</p>
<p><strong>公允价值折扣估计：</strong> 49.9%</p>
<p>Unity Software 的交易价格为 27.72 美元，显著低于其估计的未来现金流价值 55.28 美元。尽管最近内部人士出售股票且股价波动，但 Unity 的战略举措——如停止 ironSource 广告网络和剥离 Supersonic——旨在提升收入增长和利润率。与 Meta 的长期合作进一步增强了其虚拟现实平台的存在。Unity 预计将在三年内实现盈利，收益预计将以每年 62.95% 的速度大幅增长。</p>
<ul>
<li>我们编制的增长报告表明，Unity Software 的未来前景可能向好。</li>
<li>在这份财务健康报告中解锁我们对 Unity Software 股票分析的全面见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/81b649ee-0ebc-4d90-9c59-c6ef29110c9d/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/81b649ee-0ebc-4d90-9c59-c6ef29110c9d/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>截至 2026 年 5 月的 U 折现现金流</p>
<h2>下一步</h2>
<ul>
<li>点击这里揭示我们基于现金流的 151 只低估美国股票中的隐藏宝藏。</li>
<li>是这些公司的股东之一？确保您不会错过重要的股票动态，通过在 Simply Wall St 中添加您的投资组合来及时获取提醒。</li>
<li>通过使用 Simply Wall St 加入聪明投资者的社区。它是免费的，并提供全球市场的专家级分析。</li>
</ul>
<h2>想探索一些替代方案吗？</h2>
<ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>通过提供可靠的收入来源来分散您的投资组合，以应对潜在的市场波动。</li>
<li>投资于显示强劲增长潜力的公司，获得分析师和管理层的乐观展望支持。</li>
</ul>
<p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不旨在提供财务建议。它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。</strong> 我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。</em></p>
<h3>估值是复杂的，但我们在这里为您简化它。</h3>
<p>通过我们的详细分析，发现 Travere Therapeutics 是否可能被低估或高估，分析内容包括 <strong>公允价值估算、潜在风险、股息、内部交易和财务状况。</strong></p>
<p>获取免费分析</p>

TVTX

CVR能源

<p>三只股票被认为交易价格显著低于其内在价值，呈现出潜在的投资机会。Unity Software (U) 的交易价格为 27.72 美元，比其估计的公允价值 55.28 美元低 49.9%。Travere Therapeutics (TVTX) 的价格为 44.91 美元，比其公允价值 88.58 美元低 49.3%。CVR Energy (CVI) 的交易价格为 34.20 美元，比其估计价值 47.72 美元低 28.3%。尽管当前市场面临挑战，这些公司显示出良好的增长潜力，预计 Unity 的收益增长率为 62.95%，Travere 的收益增长率为 20.3%</p>

<p>Over the last 7 days, the United States market has remained flat, yet it has seen a significant rise of 28% over the past year, with earnings projected to grow by 16% annually in the coming years. In such an environment, identifying stocks that are trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on undervaluation.</p>
<div class="lb-trans"><p>在过去的 7 天里，美国市场保持平稳，但在过去一年中却显著上涨了 28%，预计未来几年收益将以每年 16% 的速度增长。在这样的环境下，识别那些交易价格低于其内在价值的股票，可以为寻求利用低估机会的投资者提供潜在的机会。</p>
</div><h3>Top 10 Undervalued Stocks Based On Cash Flows In The United States</h3>
<div class="lb-trans"><h3>基于现金流的美国十大低估股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Current Price</strong></td>
<td><strong>Fair Value (Est)</strong></td>
<td><strong>Discount (Est)</strong></td>
</tr>
<tr>
<td>Unity Software (U)</td>
<td>$27.72</td>
<td>$55.28</td>
<td>49.9%</td>
</tr>
<tr>
<td>Travere Therapeutics (TVTX)</td>
<td>$44.91</td>
<td>$88.58</td>
<td>49.3%</td>
</tr>
<tr>
<td>Sea (SE)</td>
<td>$85.41</td>
<td>$169.85</td>
<td>49.7%</td>
</tr>
<tr>
<td>Genuine Parts (GPC)</td>
<td>$103.52</td>
<td>$199.62</td>
<td>48.1%</td>
</tr>
<tr>
<td>First Merchants (FRME)</td>
<td>$40.02</td>
<td>$77.51</td>
<td>48.4%</td>
</tr>
<tr>
<td>Fifth Third Bancorp (FITB)</td>
<td>$49.40</td>
<td>$94.92</td>
<td>48%</td>
</tr>
<tr>
<td>FB Financial (FBK)</td>
<td>$53.53</td>
<td>$103.19</td>
<td>48.1%</td>
</tr>
<tr>
<td>Chemung Financial (CHMG)</td>
<td>$65.75</td>
<td>$127.22</td>
<td>48.3%</td>
</tr>
<tr>
<td>AST SpaceMobile (ASTS)</td>
<td>$68.43</td>
<td>$132.99</td>
<td>48.5%</td>
</tr>
<tr>
<td>AbbVie (ABBV)</td>
<td>$208.16</td>
<td>$400.51</td>
<td>48%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>当前价格</strong></td>
<td><strong>公允价值（估计）</strong></td>
<td><strong>折扣（估计）</strong></td>
</tr>
<tr>
<td>Unity Software (U)</td>
<td>$27.72</td>
<td>$55.28</td>
<td>49.9%</td>
</tr>
<tr>
<td>Travere Therapeutics (TVTX)</td>
<td>$44.91</td>
<td>$88.58</td>
<td>49.3%</td>
</tr>
<tr>
<td>Sea (SE)</td>
<td>$85.41</td>
<td>$169.85</td>
<td>49.7%</td>
</tr>
<tr>
<td>Genuine Parts (GPC)</td>
<td>$103.52</td>
<td>$199.62</td>
<td>48.1%</td>
</tr>
<tr>
<td>First Merchants (FRME)</td>
<td>$40.02</td>
<td>$77.51</td>
<td>48.4%</td>
</tr>
<tr>
<td>Fifth Third Bancorp (FITB)</td>
<td>$49.40</td>
<td>$94.92</td>
<td>48%</td>
</tr>
<tr>
<td>FB Financial (FBK)</td>
<td>$53.53</td>
<td>$103.19</td>
<td>48.1%</td>
</tr>
<tr>
<td>Chemung Financial (CHMG)</td>
<td>$65.75</td>
<td>$127.22</td>
<td>48.3%</td>
</tr>
<tr>
<td>AST SpaceMobile (ASTS)</td>
<td>$68.43</td>
<td>$132.99</td>
<td>48.5%</td>
</tr>
<tr>
<td>AbbVie (ABBV)</td>
<td>$208.16</td>
<td>$400.51</td>
<td>48%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 151 stocks from our Undervalued US Stocks Based On Cash Flows screener.</p>
<div class="lb-trans"><p>点击这里查看我们基于现金流的 151 只低估美国股票的完整列表。</p>
</div><p>Let's uncover some gems from our specialized screener.</p>
<div class="lb-trans"><p>让我们从我们的专业筛选器中发现一些宝藏。</p>
</div><h2>Travere Therapeutics (TVTX)</h2>
<div class="lb-trans"><h2>Travere Therapeutics (TVTX)</h2>
</div><p><strong>Overview:</strong> Travere Therapeutics, Inc. is a biopharmaceutical company focused on identifying, developing, and delivering therapies for rare kidney and metabolic diseases in the United States, with a market cap of $4.08 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Travere Therapeutics, Inc.是一家生物制药公司，专注于识别、开发和提供针对美国罕见肾脏和代谢疾病的治疗，市值为 40.8 亿美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue of $490.73 million from the development and commercialization of innovative therapies for rare kidney and metabolic diseases in the United States.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司通过开发和商业化针对美国罕见肾脏和代谢疾病的创新疗法，产生了 4.9073 亿美元的收入。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 49.3%</p>
<div class="lb-trans"><p><strong>公允价值折扣估计：</strong> 49.3%</p>
</div><p>Travere Therapeutics is trading at US$44.91, significantly below its estimated future cash flow value of US$88.58, suggesting it may be undervalued based on cash flows. The company reported Q1 2026 revenue of US$127.2 million, up from US$81.73 million a year ago, and reduced its net loss to US$37.1 million from US$41.23 million last year. With FDA approval for FILSPARI expanding its market potential, Travere's revenue is forecasted to grow at 20.3% annually, outpacing the broader U.S market growth expectations.</p>
<div class="lb-trans"><p>Travere Therapeutics 的交易价格为 44.91 美元，显著低于其估计的未来现金流价值 88.58 美元，表明其可能在现金流基础上被低估。该公司报告 2026 年第一季度收入为 1.272 亿美元，较去年同期的 8173 万美元有所增长，净亏损减少至 3710 万美元，去年为 4123 万美元。随着 FDA 批准 FILSPARI 扩大其市场潜力，Travere 的收入预计将以每年 20.3% 的速度增长，超过美国市场的整体增长预期。</p>
</div><ul>
<li>In light of our recent growth report, it seems possible that Travere Therapeutics' financial performance will exceed current levels.</li>
<li>Get an in-depth perspective on Travere Therapeutics' balance sheet by reading our health report here.</li>
</ul>
<div class="lb-trans"><ul>
<li>根据我们最近的增长报告，Travere Therapeutics 的财务表现似乎有可能超过当前水平。</li>
<li>通过阅读我们的健康报告，深入了解 Travere Therapeutics 的资产负债表。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8a367f73-a6f2-4b6f-b781-0538bd368fa3/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/8a367f73-a6f2-4b6f-b781-0538bd368fa3/chart/dcf?theme=light"/></p>
<p>TVTX Discounted Cash Flow as at May 2026</p>
<div class="lb-trans"><p>截至 2026 年 5 月的 TVTX 折现现金流</p>
</div><h2>CVR Energy (CVI)</h2>
<div class="lb-trans"><h2>CVR Energy (CVI)</h2>
</div><p><strong>Overview:</strong> CVR Energy, Inc. operates in the United States focusing on renewable fuels and petroleum refining and marketing, as well as nitrogen fertilizer manufacturing, with a market cap of $3.35 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> CVR Energy, Inc.在美国运营，专注于可再生燃料和石油精炼及营销，以及氮肥制造，市值为 33.5 亿美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue through its operations in renewable fuels, petroleum refining and marketing, and nitrogen fertilizer manufacturing in the United States.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司通过在可再生燃料、石油精炼和营销以及氮肥制造方面的业务产生收入。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 28.3%</p>
<div class="lb-trans"><p><strong>公允价值折扣估计：</strong> 28.3%</p>
</div><p>CVR Energy is trading at US$34.2, below its estimated future cash flow value of US$47.72, highlighting potential undervaluation based on cash flows. Despite a recent Q1 2026 net loss of US$192 million and earnings challenges, the company expects to become profitable within three years with high forecasted return on equity. However, revenue growth remains sluggish at 0.6% annually, trailing the broader U.S market's expectations of 11.2%.</p>
<div class="lb-trans"><p>CVR Energy 的交易价格为 34.2 美元，低于其估计的未来现金流价值 47.72 美元，突显出基于现金流的潜在低估。尽管最近 2026 年第一季度净亏损为 1.92 亿美元，且面临盈利挑战，但该公司预计将在三年内实现盈利，并且预计股本回报率将很高。然而，收入增长仍然缓慢，年增长率为 0.6%，落后于美国市场 11.2% 的预期。</p>
</div><ul>
<li>According our earnings growth report, there's an indication that CVR Energy might be ready to expand.</li>
<li>Navigate through the intricacies of CVR Energy with our comprehensive financial health report here.</li>
</ul>
<div class="lb-trans"><ul>
<li>根据我们的收益增长报告，CVR Energy 可能准备扩张的迹象。</li>
<li>通过我们的全面财务健康报告，深入了解 CVR Energy 的复杂情况。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/85096f12-bc2f-4422-bac7-9d19553b4370/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/85096f12-bc2f-4422-bac7-9d19553b4370/chart/dcf?theme=light"/></p>
<p>CVI Discounted Cash Flow as at May 2026</p>
<div class="lb-trans"><p>截至 2026 年 5 月的 CVI 折现现金流</p>
</div><h2>Unity Software (U)</h2>
<div class="lb-trans"><h2>Unity Software (U)</h2>
</div><p><strong>Overview:</strong> Unity Software Inc. provides a platform for developing, deploying, and enhancing games and interactive experiences across various devices globally, with a market cap of approximately $11.84 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Unity Software Inc.提供一个平台，用于在全球各种设备上开发、部署和增强游戏及互动体验，市值约为 118.4 亿美元。</p>
</div><p><strong>Operations:</strong> The company's revenue from Software Solutions is $1.85 billion.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司的软件解决方案收入为 18.5 亿美元。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 49.9%</p>
<div class="lb-trans"><p><strong>公允价值折扣估计：</strong> 49.9%</p>
</div><p>Unity Software, trading at US$27.72, is significantly undervalued compared to its estimated future cash flow value of US$55.28. Despite recent insider selling and a volatile share price, Unity's strategic moves—such as discontinuing the ironSource Ads Network and divesting Supersonic—aim to enhance revenue growth and margins. The extended partnership with Meta further strengthens its VR platform presence. Unity anticipates profitability within three years, with earnings forecasted to grow substantially at 62.95% annually.</p>
<div class="lb-trans"><p>Unity Software 的交易价格为 27.72 美元，显著低于其估计的未来现金流价值 55.28 美元。尽管最近内部人士出售股票且股价波动，但 Unity 的战略举措——如停止 ironSource 广告网络和剥离 Supersonic——旨在提升收入增长和利润率。与 Meta 的长期合作进一步增强了其虚拟现实平台的存在。Unity 预计将在三年内实现盈利，收益预计将以每年 62.95% 的速度大幅增长。</p>
</div><ul>
<li>The growth report we've compiled suggests that Unity Software's future prospects could be on the up.</li>
<li>Unlock comprehensive insights into our analysis of Unity Software stock in this financial health report.</li>
</ul>
<div class="lb-trans"><ul>
<li>我们编制的增长报告表明，Unity Software 的未来前景可能向好。</li>
<li>在这份财务健康报告中解锁我们对 Unity Software 股票分析的全面见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/81b649ee-0ebc-4d90-9c59-c6ef29110c9d/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/81b649ee-0ebc-4d90-9c59-c6ef29110c9d/chart/dcf?theme=light"/></p>
<p>U Discounted Cash Flow as at May 2026</p>
<div class="lb-trans"><p>截至 2026 年 5 月的 U 折现现金流</p>
</div><h2>Next Steps</h2>
<div class="lb-trans"><h2>下一步</h2>
</div><ul>
<li>Reveal the 151 hidden gems among our Undervalued US Stocks Based On Cash Flows screener with a single click here.</li>
<li>Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.</li>
<li>Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里揭示我们基于现金流的 151 只低估美国股票中的隐藏宝藏。</li>
<li>是这些公司的股东之一？确保您不会错过重要的股票动态，通过在 Simply Wall St 中添加您的投资组合来及时获取提醒。</li>
<li>通过使用 Simply Wall St 加入聪明投资者的社区。它是免费的，并提供全球市场的专家级分析。</li>
</ul>
</div><h2>Want To Explore Some Alternatives?</h2>
<div class="lb-trans"><h2>想探索一些替代方案吗？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>通过提供可靠的收入来源来分散您的投资组合，以应对潜在的市场波动。</li>
<li>投资于显示强劲增长潜力的公司，获得分析师和管理层的乐观展望支持。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation.</strong> We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不旨在提供财务建议。它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。</strong> 我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。</em></p>
</div><h3>Valuation is complex, but we're here to simplify it.</h3>
<div class="lb-trans"><h3>估值是复杂的，但我们在这里为您简化它。</h3>
</div><p>Discover if Travere Therapeutics might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p>
<div class="lb-trans"><p>通过我们的详细分析，发现 Travere Therapeutics 是否可能被低估或高估，分析内容包括 <strong>公允价值估算、潜在风险、股息、内部交易和财务状况。</strong></p>
</div><p>Access Free Analysis</p>
<div class="lb-trans"><p>获取免费分析</p>
</div>

3 只股票估计交易价格低于内在价值最多达 49.9%